Studies on Cannabinoid Effects and Cannabimimetic Drugs

大麻素效应和大麻模拟药物的研究

基本信息

  • 批准号:
    7596441
  • 负责人:
  • 金额:
    $ 11.93万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2000
  • 资助国家:
    美国
  • 起止时间:
    2000-09-30 至 2011-03-31
  • 项目状态:
    已结题

项目摘要

This is a request for renewal of my K05 Senior Scientist Award. During the past fifteen years important developments in the field of cannabinoid research have placed it in the center of biomedical research. The K05 Award has allowed me to enhance my scientific activities in this field. It has also facilitated expansion of my mentorship activities, including those directed towards under-represented minorities. Renewal of the Award will make it possible for me to continue this highly productive effort. It will allow me to regularly modernize techniques being used in my laboratory and introduce novel, state of the art technologies, including: a) the use of liquid chromatography/mass spectroscopy (LC/MS) methods for studying the structure of the GPCRs; b) the use of LC/MS methods in projects on targeted proteomics and targeted metabolomics; c) the use of molecular biological and genomics approaches to characterize and modify known endocannabinoid targets, and search for novel ones; d) the continued use of novel multidimensional NMR techniques (liquids and solids) to study key endocannabinoid proteins and their interactions with cannabinergic ligands, and e) the continued development of novel in vivo imaging approaches. The proposed research is directed towards understanding the molecular bases of cannabinoid activity, many of which are elicited through the endogenous cannabinoid biochemical system. This involves two families of endogenous ligands (endocannabinoids) represented by anandamide and 2-arachidonoylglycerol (2-AG), both of which induce their physiological responses by interacting with the two known cannabinoid receptors (CB1 and CB2). Endocannabinoid signaling is also modulated by the biochemical processes involved in the deactivation of endocannabinoid ligands, including the two known hydrolytic enzymes, fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MGL), the oxidative enzyme cycloxygenase 2 (COX2) and cellular anandamide reuptake processes that remain to be fully characterized. My research program will continue to focus on understanding the structural requirements involved in the interactions of cannabinergic ligands with each of the target proteins. Such information will be utilized in the design of novel first generation ligands and improved later generation analogs. These compounds can serve as medications to treat drug abuse and assist in the resolution of this important public health problem. The work proposed under this Award will involve a multifaceted approach involving ligand design and synthesis, biophysical and computational chemistry, and biochemical experiments. The results should reveal the molecular properties required for cannabinergic activity (the pharmacophore requirements), and assist in the design of more effective ligands which can serve as useful pharmacological tools, imaging agents, or candidate medications to treat addictive disorders and other illnesses.
这是我的 K05 高级科学家奖续展请求。在过去的十五年里,重要的是 大麻素研究领域的发展使其成为生物医学研究的中心。这 K05 奖使我能够加强我在这一领域的科学活动。也有利于扩大规模 我的指导活动,包括针对代表性不足的少数群体的指导活动。续订 奖项将使我能够继续这一卓有成效的努力。它将使我能够定期 使我的实验室使用的技术现代化并引入新颖的、最先进的技术, 包括: a) 使用液相色谱/质谱 (LC/MS) 方法来研究 GPCR 的结构; b) LC/MS 方法在靶向蛋白质组学和靶向药物项目中的使用 代谢组学; c) 使用分子生物学和基因组学方法来表征和修改 已知的内源性大麻素目标,并寻找新的目标; d) 继续使用新颖的多维 核磁共振技术(液体和固体)研究关键的内源性大麻素蛋白及其与 大麻能配体,以及 e) 新型体内成像方法的持续发展。 拟议的研究旨在了解大麻素活性的分子基础, 其中许多是通过内源性大麻素生化系统引起的。这涉及到两个 以 anandamide 和 2-arachidonoylglycerol 为代表的内源性配体(内源性大麻素)家族 (2-AG),两者都通过与两种已知的大麻素相互作用来诱导其生理反应 受体(CB1 和 CB2)。内源性大麻素信号传导也受到生化过程的调节 参与内源性大麻素配体的失活,包括两种已知的水解酶:脂肪酶 酰胺水解酶 (FAAH) 和单酰甘油脂肪酶 (MGL)、氧化酶环加氧酶 2 (COX2) 和细胞 anandamide 再摄取过程仍有待充分表征。 我的研究计划将继续侧重于了解涉及的结构要求 大麻能配体与每种靶蛋白的相互作用。此类信息将用于 设计新颖的第一代配体和改进的新一代类似物。这些化合物可以起到 作为治疗药物滥用并协助解决这一重要公共卫生问题的药物。 该奖项提出的工作将涉及多方面的方法,包括配体设计和 合成、生物物理和计算化学以及生物化学实验。结果应该 揭示大麻能活性所需的分子特性(药效团要求),以及 协助设计更有效的配体,这些配体可以作为有用的药理学工具、成像 治疗成瘾性疾病和其他疾病的药物或候选药物。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Alexandros Makriyannis其他文献

Alexandros Makriyannis的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Alexandros Makriyannis', 18)}}的其他基金

Targeting Inflammasome with stable endocannabinoid ligand AMG315. CRISPR/Cas9 and nanotechnology study in the context of HIV and cannabinoid
使用稳定的内源性大麻素配体 AMG315 靶向炎症体。
  • 批准号:
    10085922
  • 财政年份:
    2020
  • 资助金额:
    $ 11.93万
  • 项目类别:
Targeting Inflammasome with stable endocannabinoid ligand AMG315. CRISPR/Cas9 and nanotechnology study in the context of HIV and cannabinoid
使用稳定的内源性大麻素配体 AMG315 靶向炎症体。
  • 批准号:
    10620752
  • 财政年份:
    2020
  • 资助金额:
    $ 11.93万
  • 项目类别:
CB1 Neutral Antagonists for Alcohol Use Disorder
CB1 中性拮抗剂治疗酒精使用障碍
  • 批准号:
    10928929
  • 财政年份:
    2020
  • 资助金额:
    $ 11.93万
  • 项目类别:
CB1 Neutral Antagonists for Alcohol Use Disorder
CB1 中性拮抗剂治疗酒精使用障碍
  • 批准号:
    10679060
  • 财政年份:
    2020
  • 资助金额:
    $ 11.93万
  • 项目类别:
Targeting Inflammasome with stable endocannabinoid ligand AMG315. CRISPR/Cas9 and nanotechnology study in the context of HIV and cannabinoid
使用稳定的内源性大麻素配体 AMG315 靶向炎症体。
  • 批准号:
    10197872
  • 财政年份:
    2020
  • 资助金额:
    $ 11.93万
  • 项目类别:
Targeting Inflammasome with stable endocannabinoid ligand AMG315. CRISPR/Cas9 and nanotechnology study in the context of HIV and cannabinoid
使用稳定的内源性大麻素配体 AMG315 靶向炎症体。
  • 批准号:
    10404955
  • 财政年份:
    2020
  • 资助金额:
    $ 11.93万
  • 项目类别:
CB1 Neutral Antagonists for Alcohol Use Disorder
CB1 中性拮抗剂治疗酒精使用障碍
  • 批准号:
    10266861
  • 财政年份:
    2020
  • 资助金额:
    $ 11.93万
  • 项目类别:
Effect of a potent and metabolically stable endocannabinoid receptor agonist on inflammasome-induced neuroinflammation in a comorbid mouse model of Alzheimer's disease and HIV
一种有效且代谢稳定的内源性大麻素受体激动剂对阿尔茨海默病和艾滋病毒共病小鼠模型中炎症小体诱导的神经炎症的影响
  • 批准号:
    10285175
  • 财政年份:
    2020
  • 资助金额:
    $ 11.93万
  • 项目类别:
CB1 Neutral Antagonists for Alcohol Use Disorder
CB1 中性拮抗剂治疗酒精使用障碍
  • 批准号:
    10475285
  • 财政年份:
    2020
  • 资助金额:
    $ 11.93万
  • 项目类别:
Medications for Synthetic Cannabinoid Abuse
合成大麻素滥用药物
  • 批准号:
    9558524
  • 财政年份:
    2019
  • 资助金额:
    $ 11.93万
  • 项目类别:

相似国自然基金

大麻CB2受体及其激动剂AM1241在帕金森病运动并发症发病机制中的作用研究
  • 批准号:
    81400927
  • 批准年份:
    2014
  • 资助金额:
    22.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Matricelluar-mediated cell migration in tumor cells
肿瘤细胞中基质细胞介导的细胞迁移
  • 批准号:
    8849682
  • 财政年份:
    2013
  • 资助金额:
    $ 11.93万
  • 项目类别:
Heterodimerization of CXCR4 and CB2 Inhibits Prostate Cancer Cell Movement
CXCR4 和 CB2 的异二聚化抑制前列腺癌细胞运动
  • 批准号:
    8733741
  • 财政年份:
    2013
  • 资助金额:
    $ 11.93万
  • 项目类别:
Heterodimerization of CXCR4 and CB2 Inhibits Prostate Cancer Cell Movement
CXCR4 和 CB2 的异二聚化抑制前列腺癌细胞运动
  • 批准号:
    8489689
  • 财政年份:
    2013
  • 资助金额:
    $ 11.93万
  • 项目类别:
Cannabinoid CB2 Agonists for Treatment of Breast Cancer-Induced Bone Pain
大麻素 CB2 激动剂用于治疗乳腺癌引起的骨痛
  • 批准号:
    8606826
  • 财政年份:
    2010
  • 资助金额:
    $ 11.93万
  • 项目类别:
Cannabinoid CB2 Agonists for Treatment of Breast Cancer-Induced Bone Pain
大麻素 CB2 激动剂用于治疗乳腺癌引起的骨痛
  • 批准号:
    8212471
  • 财政年份:
    2010
  • 资助金额:
    $ 11.93万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了